Avalyn Pharma raises $345M in upsized IPO at $1.1B valuation
What's the deal? Avalyn Pharma, a Boston biotech developing inhaled therapies for rare respiratory diseases, raised $345 million in an upsized IPO. It began trading on the Nasdaq in April 2026 at a $1.1 billion valuation.
What's the endgame? Avalyn delivers medicines directly to lung tissue to boost efficiency and avoid side effects from systemic drug delivery. Its lead asset, AP01, is an inhaled version of pirfenidone, a small molecule inhibitor.
Why now? Chief financial officer and chief business officer Doug Carlson called the offering "above and beyond expectations." He said it lets the company "really think about things like pipeline expansion and other ways to continue to build the business."
What led up to it? The IPO process took four months, but chief executive officer Lyn Baranowski laid the groundwork much earlier. Since joining four years ago, she diversified a shareholder base of mostly early-stage investors, bringing in later-stage and public-market backers.
She also recruited Carlson in 2024 for his experience taking a company public. He previously led a $144 million IPO as chief financial officer and chief operating officer of Ikena Oncology.
What it took: The two executives worked 12- to 16-hour days, often meeting on Sunday afternoons to catch up. During two weeks of testing-the-waters meetings, Baranowski met around 100 investors one on one, pushing her days to 16 hours.
"Getting through that, that was probably the most exhausting month for me personally because I had to tell the story every time and make it feel fresh and exciting for them and me," she said.
The signal: Avalyn's upsized offering shows public-market appetite for clinical-stage biotechs with differentiated delivery platforms. The extra capital gives the company room to expand its pipeline beyond a single lead asset.
Image credit: f097653195018
Read more: BioSpace
